Oppenheimer analyst Wendy Lam is out with her second defense of bluebird bio (NASDAQ: BLUE) today amid the 20% sell-off ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE